Lumos Diagnostics Receives Initial Blood Test Purchase Order Under Distribution Agreement; Shares Up 7%
MT Newswires Live
Aug 04
Lumos Diagnostics Holdings (ASX:LDX) received an initial $767,800 purchase order from Phase Scientific for its FebriDx blood test, satisfying part of the year one minimum order quantity commitment under a distribution agreement with Phase Scientific, according to a Tuesday Australian bourse filing.
The order is associated with the $5 million prepayment milestone received by Lumos following the grant of the CLIA waiver for FebriDx by the US Food and Drug Administration on March 27.
Product delivery is expected to be fulfilled progressively between Tuesday and October.
The company's shares climbed nearly 7% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.